TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05408780
Drug: AC-OLE-01-VA
Normalized name: VP/VA COPOLYMER
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: formulation of tricaprilin or matching placebo
Study: NCT05325684
Drug: PD-L1 inhibitor
Normalized name: dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enrolled patients received durvalumab/ Atezolizumab plus chemotherapy or target therapy treatment (durvalumab,1000mg，iv, d1, 21day as a cycle; Atezolizumab,1200mg iv, d1, 21day as a cycle.)
Study: NCT05766605
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study: NCT05766605
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Study: NCT05766605
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Study: NCT05766605
Drug: Lobaplatin, Raltitrexed
DrugBank: Raltitrexed (DB00293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study: NCT00002193
Drug: Amprenavir
Normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT04582591
Drug: Cannabidiol 100 MG/ML
Normalized name: cannabidiol 100 MG/ML
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients receive cannabidiol before and after treatment with chemotherapy
Study: NCT04769869
Drug: AZD4604 for IV administration
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy volunteers will receive a single IV dose of AZD4604 administered over 20 minutes. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study: NCT04769869
Drug: AZD4604 for oral administration
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Healthy volunteers will receive a single PO dose of AZD4604. The dose will be administered after an overnight fast of at least 10 hours. Healthy volunteers will be allowed to drink water to prevent dehydration until 1 hour before dosing.
Study: NCT04943679
Drug: PEG-Interferon Alfa
Normalized name: PEG-Interferon alfa-2A
DrugBank: Interferon alfa (DB05258)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 µg/kg every week by subcutaneous injection for up to 2 years
Study: NCT05965219
Drug: Emraclidine
Normalized name: Emraclidine
DrugBank: Emraclidine (DB18706)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emraclidine tablets.
Study: NCT05965219
Drug: Itraconazole
Normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Itraconazole oral solution.
Study: NCT05965219
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine tablets.
Study: NCT05965219
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin tablets.
Study: NCT04368819
Drug: Allopurinol 300 MG
Normalized name: allopurinol 300 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol 300mg once daily for four weeks followed by allopurinol 300mg twice daily for 12 weeks
Study: NCT06080555
Drug: Ferric Carboxymaltose Injection
Normalized name: ferric carboxymaltose Injection
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: For the T group, participants will have a standardized dinner on the night before the trial, followed by a fasting period of at least 10 h before receiving the test product (T, 10 mL: 500 mg elemental iron) via intravenous injection in the single upper limb, at a continuous rate for 5 min, with a speed of 2 mL/min.
Study: NCT05772871
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone, oral administration, recommended dose: 2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks. If patients have relapsed during reducing dosage or withdrawal, the patients will receive Prednisone for 8 weeks again \[2mg/kg/d (maximum 60 mg/d) for 4 weeks followed by 2 mg/kg (maximum 60mg) on alternate days for the other 4 weeks\]. If a second relapse is observed, patients will receive immunosuppressants and then withdraw from the trial.
Study: NCT05772871
Drug: Levamisole placebo
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole placebo, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study: NCT05772871
Drug: Levamisole
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole, 1.25 mg/kg. once daily. Continuous medication until the end of the study (6 months), second relapse, development as steroid-resistant, lost to follow-up, withdrawal from the study for any reason, or death, whichever occurs first.
Study: NCT05002725
Drug: Lidocain
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 300mg (20ml) will be injected
Study: NCT03919162
Drug: PQ912
Normalized name: Pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: PQ912 150 mg tablets
Study: NCT05270863
Drug: Carbachol PF
Normalized name: Carbachol
DrugBank: Carbamoylcholine (DB00411)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single drop in each eye at a visit.
Study: NCT05270863
Drug: Brimonidine tartrate
Normalized name: Brimonidine Tartrate
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single drop in each eye at a visit.
Study: NCT06194656
Drug: HER3 Monoclonal antibodies-Dose A
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose A, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study: NCT06194656
Drug: HER3 Monoclonal antibodies-Dose B
Normalized name: B-CELL MATURATION ANTIGEN (BCMA) CLUSTER OF DIFFERENTIATION 3 (CD3) BISPECIFIC MONOCLONAL ANTIBODY (MAB) ANTI-BCMA/ANTI-CD3 BISPECIFIC MAB
DrugBank: Elranatamab (DB15395)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose B, intravenous infusion (IV), once every three weeks, 21 days as a cycle. The infusion time is 90 min (± 5 min).
Study: NCT05209035
Drug: Trazodone
Normalized name: Trazodone
DrugBank: Trazodone (DB00656)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trazodone 50mg daily
Study: NCT02780193
Drug: Omegaven
Normalized name: Omegaven
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
Study: NCT04992143
Drug: Tilelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilelizumab 240mg per 3weeks ivgtt within 1 week after the first TACE
Study: NCT04992143
Drug: Sorafenib
Normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib should be administered 400 mg twice /day orally within 1 week after the first TACE
Study: NCT04972253
Drug: Infigratinib
Normalized name: INFIGRATINIB
DrugBank: Infigratinib (DB11886)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral, dosage per protocol
Study: NCT05716945
Drug: Fluorometholone 0.1% Oph Susp
Normalized name: FLUOROMETHOLONE 0.1% OPH SUSP
DrugBank: Fluorometholone (DB00324)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Year 1: DMS 0.1% 6 times a day for 1 month followed by FML 0.1% 4 times a day for two months tapered off to once daily within four months and then once a day for 6 months.~Year 2: Half the patients in each study arm will use FML 0.1% daily.
Study: NCT05716945
Drug: Dexamethasone 0.1% ophthalmic suspension
Normalized name: Dexamethasone 0.1% Ophthalmic Suspension
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Year 1: DMS 0.1% 6 times a day for 1 month tapered off to once daily within 6 months and then once a day for 6 months.
Study: NCT06426979
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FEMARA 2.5 mg tablets two tablets daily
Study: NCT06529432
Drug: Bupivacaine Liposome Injection
Normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine Liposome Injection Low Dose or Moderate Dose or High Dose
Study: NCT06529432
Drug: Bupivacaine Hydrochloride Injection
Normalized name: Bupivacaine Hydrochloride Injection
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine Hydrochloride Injection Low Dose or Moderate Dose or High Dose
Study: NCT06527885
Drug: Lurasidone
Normalized name: Lurasidone
DrugBank: Lurasidone (DB08815)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients treated with Lurasidone in according to routine clinical practice, in Italy
Study: NCT06306001
Drug: Methylene Blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the intervention arm will receive a 1 mg/kg bolus of methylene blue over 30 minutes, followed by an infusion of 0.15 mg/kg/h. The infusion rate may be increased in steps of 0.15 mg/kg/h every 30 minutes until a maximum of 0.5 mg/kg/h.
Study: NCT06310382
Drug: GH55
Normalized name: Ghrelin
DrugBank: Lenomorelin (DB11895)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH55 capsule is a novel small molecule, highly selective dual-mechanism ERK1/2 inhibitor developed by Suzhou Genhouse Bio. Co., Ltd. This product can be used to treat cancers caused by abnormal activation of the MAPK pathway (mutational activation of RAS/RAF/MEK) by targeted inhibition of ERK1/2.
Study: NCT04477616
Drug: Day 7 regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 7 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
Study: NCT04477616
Drug: Day 3 regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: patients received a single dose of 6mg of PEG-rhG-CSF(pegfilgrastim), as a single subcutaneous injection on day 3 after chemotherapy. If FN occurs in the experimental group and the control group, reduce the dose of chemotherapy in the next course of treatment, timely change the chemotherapy regimen, and closely monitor to ensure patient safety. Record the results of routine blood follow-up and temperature curves of patients at different time periods. If WBC \>= 15 x 10\^9/L in the first chemotherapy cycle, then 3mg PEG-rhG-CSF will be used in the second chemotherapy cycle.
Study: NCT04765098
Drug: Tamoxifen
Normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen 20 mg daily for 3 days then 20 mg BID for 3 days then increase by 20 mg daily every 3 days until 100 mg BID continuously
Study: NCT04765098
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: etoposide 50mg/m2 daily
Study: NCT03769688
Drug: Metronidazole gel
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 day course of vaginal MetroGel will be used prior to VMT intervention.
Study: NCT06400784
Drug: Isosorbide Dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (5mg bd) and Hydralazine (25mg bd) will be added on top of conventional heart failure medications.
Study: NCT05732064
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine 0.5 microgram/kg (300 microgram/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
Study: NCT05732064
Drug: Esketamine
Normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Esketamine 0.2 mg/kg (25 mg/ml) is administered via nasal cavity at 20:00 pm the day before surgery, the day of surgery, and the first day after surgery.
Study: NCT04454515
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine is an α2 receptor agonist with sedative and analgesic properties. In previous reports, dexmedetomidine improves smoothness of postoperative recovery and reduces intraoperatory imflammatory responses. As patients receiving breast surgeries are especially vulnerable to postoperative nausea/ vomiting, the dosage of narcotics and associated complications were concerned for not only comfortness but also postoperative oral intake and discharge.
Study: NCT05986162
Drug: Itolizumab
Normalized name: Itolizumab
DrugBank: Itolizumab (DB16207)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients to be treated with Itolizumab.
Study: NCT04882176
Drug: LM-061
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subjects in each dose level will be administered single oral dose of LM-061 tablet on C0D1, and washout for 5 days. After that, the subjects will be administered multiple oral doses once daily (QD) in continuous 28 days (4 weeks) per treatment cycle, until meet the treatment termination criteria, including disease progression or unaccepted toxicity, etc. After obtaining MTD/RP2D, the Safety Review Committee (SRC) may combine the data of safety, PK, and preliminary efficacy to explore other dosing schedules (such as 3 weeks on and 1 week off).
Study: NCT03567694
Drug: HA115
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Test Drug
Study: NCT05136170
Drug: Cenegermin
Normalized name: Cenegermin
DrugBank: Cenegermin (DB13926)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Oxervate®, an ophthalmic solution containing cenegermin 20 mcg/mL, which is a recombinant human Nerve Growth Factor (rhNGF); one drop of the test product will be instilled in both eyes three times daily (TID) for 28 consecutive days.
Study: NCT06463184
Drug: Xevinapant
Normalized name: Xevinapant
DrugBank: Xevinapant (DB16305)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xevinapant is an investigational medication, taken orally, that promotes cancer cell death via apoptosis.
Study: NCT04675827
Drug: Pertuzumab and tratuzumab fixed dose combination
Normalized name: hyaluronidase / pertuzumab / trastuzumab
DrugBank: Pertuzumab (DB06366)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment administration: adjuvant pertuzumab and trastuzumab fixed dose combination SC for 14 cycles
Study: NCT04675827
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment administration: adjuvant T-DM1 for 14 cycles.
Study: NCT05559099
Drug: Tecovirimat Oral Capsule
Normalized name: tecovirimat Oral Capsule
DrugBank: Tecovirimat (DB12020)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 200 mg capsules~Number of capsules and frequency of dosage will be based on participant weight:~* ≥120 kg: three capsules three times a day (total daily tecovirimat dose: 1,800 mg)~* 40 to \<120 kg: three capsules twice a day (total daily tecovirimat dose: 1,200 mg)~* 25 to \<40 kg: two capsules twice a day (total daily tecovirimat dose: 800 mg)~* 13 to \<25 kg: one capsule twice a day (total daily tecovirimat dose: 400 mg)~* 6 to \<13 kg: ½ the contents of a capsule twice daily (total daily tecovirimat dose: 200 mg)~* 3 to \<6 kg: ¼ the contents of a capsule twice daily (total daily tecovirimat dose: 100 mg)
Study: NCT06211712
Drug: Experimental: Human Urinary Kallidinogenase
DrugBank: Kallidinogenase (DB13197)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before the first day of endovascular therapy (non-bridging), dissolve Human Urinary Kallidinogenase in 100 mL 0.9% sodium chloride for intravenous injection, for the next 9 days, once a day for a total of 10 days.
Study: NCT06528405
Drug: dapagliflozin
Normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study: NCT06528405
Drug: empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study: NCT06528405
Drug: canagliflozin
Normalized name: Canagliflozin
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sodium-glucose cotransporter 2 inhibitor for 90 days during the acute kidney disease period.
Study: NCT05571293
Drug: Botensilimab
Normalized name: Botensilimab
DrugBank: Botensilimab (DB16651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botensilimab, a CTLA-4 inhibitor, will be administered prior to surgical resection as described in the arm description.
Study: NCT05571293
Drug: Balstilimab
Normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balstilimab, a PD-1 inhibitor, will be administered prior to surgical resection as described in the arm description.
Study: NCT05441514
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT05441514
Drug: Enasidenib Mesylate
Normalized name: Enasidenib Mesylate
DrugBank: Enasidenib (DB13874)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT05990686
Drug: Tramadol Hydrochloride
Normalized name: Tramadol Hydrochloride
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After routine pre-operative evaluation, standard monitors will be connected to the patients: pulse oximetery, noninvasive blood pressure and electrocardiogram and baseline parameter will be recorded (heart rate, mean arterial pressure and peripheral oxygen saturation). Intravenous (IV) line will be inserted for all patients, and IV fluid will be started.~Intravenous infusion of 15mg/kg paracetamol together with 1mg/kg tramadol will be started and to be finished before starting of induction of anaesthesia (induction agent will be Propofol 2mg/kg)
Study: NCT05363592
Drug: Alogliptin Benzoate 12.5 mg
Normalized name: Alogliptin Benzoate 12.5 MG Oral Tablet
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin Benzoate 12.5 mg 2 tablets, at a time, oral administration
Study: NCT05363592
Drug: Metformin HCl XR 500 mg
Normalized name: metformin hydrochloride Extended Release Suspension
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin HCl XR 500 mg 2 tablets, at a time, oral administration
Study: NCT04800692
Drug: Tetrahydrobiopterin 10 mg/kg
DrugBank: Biopterin (DB03886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg of Tetrahydrobiopterin daily.
Study: NCT04800692
Drug: Tetrahydrobiopterin 20 mg/kg
DrugBank: Biopterin (DB03886)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20mg/kg of Tetrahydrobiopterin daily.
Study: NCT04800692
Drug: L-Ascorbate
Normalized name: L-Ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3300 mg of l-ascorbate once daily
Study: NCT04800692
Drug: L-Arginine
Normalized name: L-Arginine
DrugBank: L-arginine (DB17289)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3400mg of l-arginine once daily
Study: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 1
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Mitoxantrone Hydrochloride 16 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 2
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Mitoxantrone Hydrochloride 18 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 3
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Mitoxantrone Hydrochloride 20 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study: NCT05299164
Drug: Liposomal Mitoxantrone Hydrochloride dose level 4
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal Mitoxantrone Hydrochloride 22 mg/m\^2 (with a caret included) on day 1, every 3 weeks; Gemcitabine (800 mg/m\^2) on day 1,8, every 3 weeks; Vinorelbine (25mg/m\^2) on day 1,8, every 3 weeks; Rituximab (375mg/m\^2) on day 1, every 3 weeks, only used in patients with CD20+ lymphoma;
Study: NCT00001066
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes